

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TARO PHARMACEUTICALS U.S.A., INC.,
Petitioners,

v.

APOTEX TECHNOLOGIES INC.,
Patent Owner.

Case IPR2017-01446
U.S. Patent No. 7,049,328

PATENT OWNER'S UPDATED EXHIBIT LIST

PATENT OWNER'S UPDATED EXHIBIT LIST (37 C.F.R. § 42.63(e))

<u>Exhibit</u>	<u>Exhibit Name</u>
2001	Declaration of Thomas D. Coates, M.D.
2002	<i>Curriculum vitae</i> of Thomas D. Coates, M.D.
2003	Declaration of Dudley J. Pennell, M.D. FRCP FACC FESC FRCR FAHA FMedSci
2004	<i>Curriculum vitae</i> of Dudley J. Pennell, M.D. FRCP FACC FESC FRCR FAHA FMedSci
2005	Intentionally left blank
2006	Noetzli <i>et al.</i> , “ <i>Longitudinal analysis of heart and liver iron in thalassemia major</i> ,” BLOOD 112(7):2973-2978 (2008)
2007	L. Anderson <i>et al.</i> , “[2601] <i>Cardiac Iron Deposition Is Not Predicted By Conventional Markers Of Iron Overload In Homozygous β-Thalassemia</i> ,” ABSTRACTS OF THE 42D ANN. MTG. OF THE AMER. SOC. OF HEMATOLOGY, Dec. 1-5, 2000
2008	Internet publication dated October 14, 2011, “ <i>FDA approves FERRIPROX[®] to treat patients with excess iron in the body</i> ,” U.S. Food & Drug Administration, available at: http://www.prnewswire.com/news-releases/fda-approves-ferriprox-to-treat-patients-with-excess-iron-in-the-body-131876763.html (last accessed August 23, 2017)
2009	Intentionally left blank
2010	Claim Construction Opinion and Order, D.E. 64 in Civil Action No. 2:16-cv-0058 (E.D. Tex., May 17, 2017)
2011	N.F. Olivieri <i>et al.</i> , “ <i>Long-Term Safety and Effectiveness of Iron-Chelation Therapy With Deferiprone for Thalassemia Major</i> ,” N. ENG. J. MED. 339(7):417-423 (1998)
2012	N.F. Olivieri <i>et al.</i> , “ <i>Cardiac Failure and Myocardial Fibrosis in a patient with Thalassemia Major (TM) Treated with Long-Term Deferiprone</i> ,” BLOOD 92(10) Suppl. 1:532a (1998)
2013	N.F. Olivieri <i>et al.</i> , “ <i>Long-Term Trials of Deferiprone in Cooley’s Anemia</i> ,” ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Vol. 850:217-222 (1998)
2014	Internet publication dated June 8, 2017, “ <i>Canadian Scientists Honored in for Role in Breakthrough Drug</i> ,” Cooley’s Anemia Foundation, available at: http://www.newswire.ca/news-releases/canadian-scientists-honored-for-role-in-breakthrough-drug-627205651.html (last accessed August 23, 2017)

<u>Exhibit</u>	<u>Exhibit Name</u>
2015	L.J. Anderson <i>et al.</i> , “ <i>Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload,</i> ” EUR. HEART J. 22(23):2171-2179 (2001)
2016	L.J. Anderson <i>et al.</i> , “ <i>Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia,</i> ” LANCET 360:516-520 (2002)
2017	Statutory Disclaimer Under 37 C.F.R. § 1.321(a)
2018	Statement of Right of Assignee to Take Action Under 37 C.F.R. § 3.73(b)
2019	Patent Owner’s Notice of Deposition of Jayesh Mehta, M.D., Under 37 C.F.R. § 42.53
2020	Supplemental Declaration of Jayesh Mehta, M.D.
2021	“Future of oral iron chelator deferiprone (L1),” LANCET 341 (1993)
2022	V. Berdoukas <i>et al.</i> , “ <i>Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration,</i> ” HAEMATOLOGICA 90(5):685-686 (2005)
2023	D. Nathan, “ <i>An Orally Active Chelator,</i> ” N. ENGL. J. MED. 332(14):953-954 (1995)
2024	Deposition of Jayesh Mehta, M.D., dated February 15, 2018
2025	T.D. Coates, “ <i>Physiology and pathophysiology of iron in hemoglobin-associated diseases,</i> ” FREE RADICAL BIOLOGY AND MEDICINE 72:23-40 (2014)
2026	Second Declaration of Dudley J. Pennell, M.D., in Support of Patent Owner’s Response
2027	A. Aessopos <i>et al.</i> , “ <i>The heart in transfusion dependent homozygous thalassaemia today – prediction, prevention and management,</i> ” EUR. J. HAEMATOLOGY 80:93-106 (2008)
2028	N. Koonrungsesomboon <i>et al.</i> , “ <i>Early detection of cardiac involvement in thalassemia: From bench to bedside perspective,</i> ” WORLD J. CARDIOL. 5(8):270-279 (2013)
2029	A. Aessopos <i>et al.</i> , “ <i>Prevention of Cardiomyopathy in Transfusion-Dependent Homozygous Thalassaemia Today and the Role of Cardiac Magnetic Resonance Imaging,</i> ” ADVANCES IN HEMATOLOGY Article ID 964897:1-4 (2009)
2030	S. Lekawanvijit <i>et al.</i> , “ <i>Iron overload thalassemic cardiomyopathy: Iron status assessment and mechanisms of mechanical and electrical</i>

<u>Exhibit</u>	<u>Exhibit Name</u>
	<i>disturbance due to iron toxicity,</i> ” CAN. J. CARDIOL. 25(4):213-218 (2009)
2031	D.L. Johnston <i>et al.</i> , “ <i>Assessment of tissue iron overload by nuclear magnetic resonance imaging,</i> ” AM. J. MED. 87(1):40-47, (1989)
2032	W.H. Crosby, “ <i>Editorial: Serum ferritin fails to indicate hemochromatosis--nothing gold can stay,</i> ” N. ENGL. J. MED. 294(6):333-334 (1976)
2033	S.I. Mavrogeni <i>et al.</i> , “ <i>T2 relaxation time study of iron overload in β-thalassemia,</i> ” MAGMA 6(1):7-12 (1998)
2034	G.M. Brittenham <i>et al.</i> , “ <i>Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major,</i> ” N. ENGL. J. MED. 331:567-573 (1994)
2035	Second Declaration of Thomas D. Coates, M.D., in Support of Patent Owner’s Response
2036	A.V. Hoffbrand, “ <i>Diagnosing myocardial iron overload,</i> ” EUR. HEART J. 22:2140-2141 (2001)
2037	D.J. Pennell <i>et al.</i> , “ <i>Cardiovascular Function and Treatment in β-Thalassemia Major: A Consensus Statement From the American Heart Association,</i> ” CIRCULATION 128:281-308 (2013)
2038	Declaration of Barry P. Golob in Support of Motion for <i>Pro Hac Vice</i> Admission
2039	Non-confidential, Redacted public version of Petitioner’s Exhibit 1037
2040	Deposition of Jayesh Mehta, M.D., June 19, 2018

CERTIFICATE OF SERVICE

I hereby certify that, on June 28, 2018, I caused a true and correct copy of
the foregoing materials:

- PATENT OWNER'S UPDATED EXHIBIT LIST

to be served via electronic mail on the following attorneys of record:

Huiya Wu
Sarah Fink
GOODWIN PROCTER LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018-1405
HWu@goodwin.law.com
SFink@goodwinlaw.com

By: /s/ W. Blake Coblentz

W. Blake Coblentz
Reg. No. 57,104
COZEN O'CONNOR
1200 Nineteenth Street, N.W.
Washington, DC 20036
(202) 912-4837